Skip to main content
Premium Trial:

Request an Annual Quote

IntegenX Gets DoD Contract for Pathogen ID System

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sample prep firm IntegenX today said it has been awarded a $2.8 million contract by the US Department of Defense to develop a system for the rapid detection and identification of genetically engineered bacteria and viruses.

The contract from DoD's Defense Threat Reduction Agency is the first phase of a possible 22-month, $14.8 million contract, the Pleasanton, Calif.-based company said in a statement. The integrated sample-to-sequence system it is developing will also be used to detect and identify medically relevant bacteria and viruses, as well as emerging pathogens.

The company will use its Universal Sample Preparation Module to purify DNA from pathogen targets contained in complex matrices. The purified material will be presented to an IntegenX library construction module, then an amplification module, and finally a next-generation sequencing module. The USPM was developed with an earlier DOD contract.

IntegenX plans to apply its Move technology to integrate the complete workflow of the ISS system. The system will be less than three cubic feet, it said.

Formerly called Microchip Biotechnologies, IntegenX manufactures automated DNA- and RNA-based sample-preparation systems for life sciences, applied sciences, and diagnostics markets.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more